BACKGROUND: The Childhood Cancer Research Network (CCRN) was established within the Children's Oncology Group (COG) in July 2008 to provide a centralized pediatric cancer research registry for investigators conducting approved etiologic and survivorship studies. The authors conducted an ecological analysis to characterize CCRN catchment at >200 COG institutions by demographic characteristics, diagnosis, and geographic location to determine whether the CCRN can serve as a population-based registry for childhood cancer. METHODS: During 2009 to 2011, 18,580 US children newly diagnosed with cancer were registered in the CCRN. These observed cases were compared with age-specific, sex-specific, and race/ethnicity-specific expected numbers calculated from Surveillance, Epidemiology, and End Results (SEER) Program cancer incidence rates and 2010 US Census data. RESULTS: Overall, 42% of children (18,580 observed/44,267 expected) who were diagnosed with cancer at age <20 years were registered in the CCRN, including 45%, 57%, 51%, 44%, and 24% of those diagnosed at birth, ages 1 to 4 years, ages 5 to 9 years, ages 10 to 14 years, and ages 15 to 19 years, respectively. Some malignancies were better represented in the CCRN (leukemia, 59%; renal tumors, 67%) than others (retinoblastoma, 34%). There was little evidence of differences by sex or race/ethnicity, although rates in nonwhites were somewhat lower than rates in whites. CONCLUSIONS: Given the low observed-to-expected ratio, it will be important to identify challenges and barriers to registration to improve case ascertainment, especially for rarer diagnoses and older age groups; however, it is encouraging that some diagnoses in younger children are fairly representative of the population. Overall, the CCRN is providing centralized, real-time access to cases for research and could be used as a model for other national cooperative groups.
BACKGROUND: The Childhood Cancer Research Network (CCRN) was established within the Children's Oncology Group (COG) in July 2008 to provide a centralized pediatric cancer research registry for investigators conducting approved etiologic and survivorship studies. The authors conducted an ecological analysis to characterize CCRN catchment at >200 COG institutions by demographic characteristics, diagnosis, and geographic location to determine whether the CCRN can serve as a population-based registry for childhood cancer. METHODS: During 2009 to 2011, 18,580 US children newly diagnosed with cancer were registered in the CCRN. These observed cases were compared with age-specific, sex-specific, and race/ethnicity-specific expected numbers calculated from Surveillance, Epidemiology, and End Results (SEER) Program cancer incidence rates and 2010 US Census data. RESULTS: Overall, 42% of children (18,580 observed/44,267 expected) who were diagnosed with cancer at age <20 years were registered in the CCRN, including 45%, 57%, 51%, 44%, and 24% of those diagnosed at birth, ages 1 to 4 years, ages 5 to 9 years, ages 10 to 14 years, and ages 15 to 19 years, respectively. Some malignancies were better represented in the CCRN (leukemia, 59%; renal tumors, 67%) than others (retinoblastoma, 34%). There was little evidence of differences by sex or race/ethnicity, although rates in nonwhites were somewhat lower than rates in whites. CONCLUSIONS: Given the low observed-to-expected ratio, it will be important to identify challenges and barriers to registration to improve case ascertainment, especially for rarer diagnoses and older age groups; however, it is encouraging that some diagnoses in younger children are fairly representative of the population. Overall, the CCRN is providing centralized, real-time access to cases for research and could be used as a model for other national cooperative groups.
Authors: Eva Steliarova-Foucher; Charles Stiller; Peter Kaatsch; Franco Berrino; Jan-Willem Coebergh; Brigitte Lacour; Max Parkin Journal: Lancet Date: 2004 Dec 11-17 Impact factor: 79.321
Authors: Erin L Marcotte; Nathan Pankratz; James F Amatruda; A Lindsay Frazier; Mark Krailo; Stella Davies; Jacqueline R Starr; Ching C Lau; Michelle Roesler; Erica Langer; Caroline Hallstrom; Anthony J Hooten; Jenny N Poynter Journal: Genes Chromosomes Cancer Date: 2017-04-04 Impact factor: 5.006
Authors: Angela L Mazul; Clarice R Weinberg; Stephanie M Engel; Anna Maria Siega-Riz; Fei Zou; Kathryn S Carrier; Patricia V Basta; Zalman Vaksman; John M Maris; Sharon J Diskin; Charlene Maxen; Arlene Naranjo; Andrew F Olshan Journal: Cancer Epidemiol Date: 2019-07-04 Impact factor: 2.984
Authors: Henry E Rice; Brian R Englum; Brian C Gulack; Obinna O Adibe; Elizabeth T Tracy; Susan G Kreissman; Jonathan C Routh Journal: Pediatr Blood Cancer Date: 2015-03-21 Impact factor: 3.167
Authors: Eric J Chow; Lena E Winestone; Philip J Lupo; Lisa R Diller; Tara O Henderson; Nina S Kadan-Lottick; Jennifer M Levine; Kirsten K Ness; Smita Bhatia; Saro H Armenian Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Alberto S Pappo; Wayne L Furman; Kris A Schultz; Andrea Ferrari; Lee Helman; Mark D Krailo Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Angela L Mazul; Anna Maria Siega-Riz; Clarice R Weinberg; Stephanie M Engel; Fei Zou; Kathryn S Carrier; Patricia V Basta; Zalman Vaksman; John M Maris; Sharon J Diskin; Charlene Maxen; Arlene Naranjo; Andrew F Olshan Journal: Cancer Causes Control Date: 2016-08-19 Impact factor: 2.506
Authors: Lindsay A Williams; Nathan Pankratz; John Lane; Mark Krailo; Michelle Roesler; Michaela Richardson; A Lindsay Frazier; James F Amatruda; Jenny N Poynter Journal: Cancer Date: 2018-10-06 Impact factor: 6.860
Authors: David A Siegel; Lisa C Richardson; S Jane Henley; Reda J Wilson; Nicole F Dowling; Hannah K Weir; Eric W Tai; Natasha Buchanan Lunsford Journal: Cancer Date: 2020-07-29 Impact factor: 6.921